NanoViricides Inc. (NNVC)

[changes_iv]

The Ebola virus may be getting closer to Americans than ever, but don't expect big American drug companies to come to the rescue.

Instead, small biotech firms, academics and government agencies are leading the search for an Ebola cure.
...
Smaller biotech firms are more likely to be drawn to the project of finding a cure or vaccine thanks to the lure of government funding, good PR and the chance to make an impact, Geisbert said.

http://www.huffingtonpost.com/2014/08/05/big-pharma-ebola_n_5651855.html

All hands on deck! EbolaCide is spearheading NanoViricides, Inc. breakthrough technology and must prove efficacy, just a few weeks ahead, 2014. Signing agreement with BSL-4 lab and validation of our 5kg cGMP Pilot Plant are other immediate goals.

It appears that if EbolaCide works very well, then this could become a higher priority (and sooner into humans?). But it's not going to slow down the FluCide toxicity testing. It may delay overall FluCide development, however. ~ KMBJN

If EbolaCide efficacy is dramatically improved, evidenced by BSL-4 partner testing (likely USAMRIID) that will make FluCide more attractive to BigPharma. On the other hand, people may also start to question why not streamline regulations for FluCide as well? People may start to question, "...I don't want the flu vaccine. I'd rather have the likely low toxicity and effective FluCide." That is what headlines on EbolaCide effectiveness could do to people. The knowledge that there are other options in the event vaccines fail is very enticing.

The June 2014 report from the Department of Justice on damages paid by the U.S. Government to vaccine victims was recently published on the U.S. Department of Health and Human Resources website. There were 120 cases of vaccine injuries decided. 78 cases received compensation, while 42 cases were denied.

Most of the U.S. public is unaware that a U.S. citizen, by law, cannot sue a pharmaceutical company for damages resulting from vaccines. Congress gave them total legal immunity in 1986, and that law was upheld by the U.S. Supreme Court in 2011. There is a special "vaccine court" called the National Vaccine Injury Compensation Program that is funded through a tax on vaccines. If you are injured or killed by a vaccine, you must hire an attorney and fight tax-funded government attorneys to seek damages, as you cannot sue the drug manufacturers. As you can see from the report below, it takes years to reach a settlement, with the longest case below being settled after 11 years. Therefore, this report probably only represents a tiny fraction of the actual number of people harmed or killed by vaccines, since it is so difficult to fight the government in court to win a settlement.

http://healthimpactnews.com/2014/government-pays-damages-to-vaccine-victims-flu-shot-most-dangerous-with-gbs-and-death-settlements/

Why would the not-so-invisible hand of the FDA impose proof of toxic dose on low toxicity and effective FluCide when FluCide could very well lead away from a life threatening virus and the dangers of vaccines??? http://www.nanoviricides.com/press%20releases/2013/NanoViricides%20Inc%20Reports%20Excellent%20Safety%20Profile%20of%20Its%20Broad%20Spectrum%20anti%20Influenza%20Drug%20Candidate%20FluCide%20in%20a%20Non%20GLP%20Study.html

As part of the advanced IND-enabling development of our Injectable FluCide drug candidate, we have continued to scale up our production processes for both the backbone polymer and the ligands. We have been able to make up to 200g batches in our existing facility. We believe that we will be able to make as much as a few kilograms in a single batch in the new cGMP-capable facility. If the course of treatment of a successful Ebola drug candidate is assumed to be a few grams, we would be able to make as many as a thousand courses of treatment per batch. Our production capacity would thus be responsive to the current requirements for the containment of the Ebola epidemic in West Africa.

All hands on deck. Unequivocally, our main objective should be and is to prove EbolaCide's efficacy, just a few weeks ahead, 2014.

As I see it, the only way the FluCide program would be delayed would be if the following two conditions were present:

#1) EbolaCide2 works incredibly well

AND

#2) We receive a phenomenal amount of money from all of the agencies now committed to eradicating the disease in order to ramp up the production of the Ebola drug. ~ Dr. Eugene Seymour, CEO of NanoViricides, Inc. to drkazmd65
investorshub.advfn.com/boards/read_msg.aspx?message_id=106739780

Professor Boniuk joined the Company’s Board as an independent director in May, 2013, at the request of the Company’s executives. He says that his confidence in the Company has only continued to grow as he sees the Company’s management and execution now from a closer perspective.

When asked why he has made these investments, he explained that “As I became familiar with the technology and the various on-going programs that the Company has, it became apparent that the potential was nothing short of amazing. Dr. Diwan explained to me how it would be possible to create a novel drug against a previously unknown virus in a matter of weeks.

How do you like that not so premature enthusiasm?